Breaking New Ground

Improving outcomes for people with cancer by translating novel scientific insights into first-in-class immunotherapies

Resilient to Our Core

With grit, expertise and passion, our scientists are enabling transformational shifts in cancer treatment

We believe that through dedication and with teams that transcend corporate walls, we can transform patient lives

October 14, 2021
Tizona Initiates Phase 1b Expansion Study of TTX-080 in Advanced Refractory or Resistant Malignancies

September 15, 2020
Tizona Appoints Christine O’Brien as Chief Executive Officer

July 21, 2020
Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million